PAHC or BSX: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks?
Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Phibro Animal Health Corporation (PAHC) Q3 2025 Earnings Call Transcript
Phibro Animal Health Corporation (NASDAQ:PAHC ) Q3 2025 Earnings Conference Call May 8, 2025 9:00 AM ET Company Participants Glenn David - Chief Financial Officer Jack Bendheim - Chairman-Board of Directors, President & Chief Executive Officer Conference Call Participants Ekaterina Knyazkova - JPMorgan Michael Ryskin - Bank of America Navann Ty - BNP Paribas Operator Hello and thank you for standing by. My name is Regina [ph] and I will be your conference operator today.
Phibro Q3 Earnings Top Estimates, Stock Up, 2025 EPS Outlook Raised
PAHC's third-quarter fiscal 2025 results reflect the strength of the Animal Health segment.
Compared to Estimates, Phibro (PAHC) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for Phibro (PAHC) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Phibro Animal Health (PAHC) Q3 Earnings Beat Estimates
Phibro Animal Health (PAHC) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.31 per share a year ago.
Phibro Animal Health (PAHC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Phibro (PAHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Phibro Animal Health (PAHC) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
PAHC or BSX: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks?
Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why Phibro (PAHC) is Poised for a Turnaround After Losing -22.25% in 4 Weeks
Phibro (PAHC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Here's Why Phibro (PAHC) is Poised for a Turnaround After Losing -13.52% in 4 Weeks
The heavy selling pressure might have exhausted for Phibro (PAHC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
